The Framingham Study, Diabetes Mellitus and Cardiovascular Disease: Turning Back the Clock

Progress in Cardiovascular Diseases

Volumn 53, Issue 1, 2010, Pages 45-51

  Kengne, Andre Pascal ^a   Turnbull, Fiona ^a   MacMahon, Stephen ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Cardiovascular disease; Diabetes mellitus; Framingham heart study; Risk factors

Indexed keywords

INSULIN; ORAL ANTIDIABETIC AGENT; TOLBUTAMIDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; MORTALITY; OBESITY; PERIPHERAL VASCULAR DISEASE; PREVALENCE; REVIEW; RISK REDUCTION; ARTICLE; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HISTORY; NATIONAL HEALTH ORGANIZATION; RISK ASSESSMENT; RISK FACTOR; TIME; UNITED STATES;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; EVIDENCE-BASED MEDICINE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); POPULATION SURVEILLANCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES;

EID: 77954165489     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2010.02.010     Document Type: Review

References (62)

1. International Diabetes Federation Diabetes atlas 2009, IDF, Brussels. 4th ed.
2. International Diabetes Federation Diabetes atlas 2003, IDF, Brussels. 2nd ed.
3. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; The National Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation International; The National Institute of Diabetes and Digestive and Kidney Diseases; and The American Heart Association. Circulation 1999, 100:1132-1133.
4. Danaei G., Lawes C.M., Vander Hoorn S., et al. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 2006, 368:1651-1659.
5. International Task Force for Prevention of Coronary Heart Disease Pocket guide to prevention of coronary heart disease 2003, International Atherosclerosis Society, Born Bruckmeier Verlag GmbH, Munster.
6. Hegglin P. Über Kreislaufprobleme bei gestörtem Zuckerstoffwechsel, insbesondere im Coma diabeticum. Basic Res Cardiol 1940, 3:1-53.
7. Mayer J. On diabetes and its connection with heart disease. BMJ 1888, 1:949-951.
8. Millard E.B., Root H.F. Degenerative vascular lesions and diabetes mellitus. Am J Dig Dis 1948, 15:41-51.
9. Smith K.S. Cardiac syndromes complicating diabetes and their treatment. Heart 1943, 5:1-7.
10. Marks H., Krall L. Onset, course, prognosis and mortality in diabetes mellitus. Joslin's diabetes mellitus 1971, 209-254. Lea & Febiger, Philadelphia. 11th ed. A. Marble, P. White, R. Bradley, L. Krall (Eds.).
11. Pyorala K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987, 3:463-524.
12. Entmacher P.S., Root H.F., Marks H.H. Longevity of diabetic patients in recent years. Diabetes 1964, 13:373-377.
13. Krolewski A.S., Czyzyk A., Janeczko D., et al. Mortality from cardiovascular diseases among diabetics. Diabetologia 1977, 13:345-350.
14. Pell S., D'Alonzo C.A. Factors associated with long-term survival of diabetics. JAMA 1970, 214:1833-1840.
15. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038.
16. Garcia M.J., McNamara P.M., Gordon T., et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974, 23:105-111.
17. Kannel W.B., Hjortland M., Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974, 34:29-34.
18. Kannel W.B., McNamara P.M., Feinleib M., et al. The unrecognized myocardial infarction. Fourteen-year follow-up experience in the Framingham study. Geriatrics 1970, 25:75-87.
19. Kannel W.B., Wilson P.W., D'Agostino R.B., et al. Sudden coronary death in women. Am Heart J 1998, 136:205-212.
20. Brand F.N., Abbott R.D., Kannel W.B. Diabetes, intermittent claudication, and risk of cardiovascular events. The Framingham Study. Diabetes 1989, 38:504-509.
21. Benjamin E.J., Levy D., Vaziri S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994, 271:840-844.
22. Wong N.D., Cupples L.A., Ostfeld A.M., et al. Risk factors for long-term coronary prognosis after initial myocardial infarction: the Framingham Study. Am J Epidemiol 1989, 130:469-480.
23. Abbott R.D., Donahue R.P., Kannel W.B., et al. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA 1988, 260:3456-3460.
24. Meinert C.L., Knatterud G.L., Prout T.E., et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970, 19(Suppl):789-830.
25. Robertson W.B., Strong J.P. Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest 1968, 18:538-551.
26. Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres. The World Health Organisation Multinational Study of Vascular Disease in Diabetics. Diabetes Drafting Group. Diabetologia 1985, 28(Suppl):615-640.
27. Asymptomatic hyperglycemia and coronary heart disease. A series of papers by the International Collaborative Group, based on studies in fifteen populations. J Chronic Dis 1979, 32:681-837. The International Collaborative Group.
28. Wilson P.W., Cupples L.A., Kannel W.B. Is hyperglycemia associated with cardiovascular disease? The Framingham Study. Am Heart J 1991, 121:586-590.
29. Kannel W.B., McGee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979, 2:120-126.
30. Levitzky Y.S., Pencina M.J., D'Agostino R.B., et al. Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study. J Am Coll Cardiol 2008, 51:264-270.
31. Fox C.S., Coady S., Sorlie P.D., et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007, 115:1544-1550.
32. Kannel W.B., Wolf P.A., Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham study. JAMA 1983, 250:2942-2946.
33. Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004, 27:2836-2842. Asia Pacific Cohort Studies Collaboration.
34. Coutinho M., Gerstein H.C., Wang Y., et al. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22:233-240.
35. Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
36. Kannel W.B., McGee D.L. Diabetes and cardiovascular risk factors: the Framingham study. Circulation 1979, 59:8-13.
37. Smoking, diabetes and cardiovascular diseases in men in the Asia-Pacific region. J Diabetes 2009, 1:173-181. Asia Pacific Cohort Studies Collaboration.
38. Cholesterol, diabetes and major cardiovascular diseases in the Asia-Pacific region. Diabetologia 2007, 50:2289-2297. Asia Pacific Cohort Studies Collaboration.
39. Systolic blood pressure, diabetes and the risk of cardiovascular diseases in the Asia-Pacific region. J Hypertens 2007, 25:1205-1213. Asia Pacific Cohort Studies Collaboration.
40. Turnbull F., Neal B., Algert C., et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419.
41. Costa J., Borges M., David C., et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006, 332:1115-1124.
42. Preis S.R., Pencina M.J., Hwang S.J., et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009, 120:212-220.
43. Fox C.S., Coady S., Sorlie P.D., et al. Trends in cardiovascular complications of diabetes. JAMA 2004, 292:2495-2499.
44. Preis S.R., Hwang S.J., Coady S., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735.
45. Fox C.S., Pencina M.J., Wilson P.W., et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008, 31:1582-1584.
46. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113:791-798.
47. Truett J., Cornfield J., Kannel W. A multivariate analysis of the risk of coronary heart disease in Framingham. J Chronic Dis 1967, 20:511-524.
48. Walker S.H., Duncan D.B. Estimation of the probability of an event as a function of several independent variables. Biometrika 1967, 54:167-179.
49. Murabito J.M., D'Agostino R.B., Silbershatz H., et al. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997, 96:44-49.
50. Anderson K.M., Odell P.M., Wilson P.W., et al. Cardiovascular disease risk profiles. Am Heart J 1991, 121:293-298.
51. Kannel W.B., McGee D., Gordon T. A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976, 38:46-51.
52. Wilson P.W., D'Agostino R.B., Levy D., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
53. D'Agostino R.B., Vasan R.S., Pencina M.J., et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008, 117:743-753.
54. Stevens R.J., Kothari V., Adler A.I., et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001, 101:671-679.
55. Chamnan P., Simmons R.K., Sharp S.J., et al. Cardiovascular risk assessment scores for people with diabetes: a systematic review. Diabetologia 2009, 52:2001-2014.
56. Kengne A.P., Patel A., Colagiuri S., et al. The Framingham and UKPDS risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 2010, 10.1007/s00125-010-1681-4.
57. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
58. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
59. Kelly T.N., Bazzano L.A., Fonseca V.A., et al. Glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:1-10.
60. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765-1772.
61. Stettler C., Allemann S., Juni P., et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006, 152:27-38.
62. Turnbull F.M., Abraira C., Anderson R.J., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009, 52:2288-2298.